AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29174216 — intervention group
Group type: COMPARATOR
Intervention: Reference product under fed conditions
Number of subjects: 30
Study 26561314 — intervention group
Group type: EXPERIMENTAL
Intervention: BAN (bananas)
Number of subjects: 20
Study 26561314 — intervention group
Group type: EXPERIMENTAL
Intervention: PEAR (pears)
Number of subjects: 20
Study 26561314 — intervention group
Group type: COMPARATOR
Intervention: WATER (control)
Number of subjects: 20
Study 24032226 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined systemic and regional chemotherapy
Number of subjects: 70
Study 24032226 — intervention group
Group type: COMPARATOR
Intervention: Systemic chemotherapy
Number of subjects: 70
Study 21211103 — intervention group
Group type: EXPERIMENTAL
Intervention: Facemasks
Number of subjects: 147
Study 21211103 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified hand hygiene measures
Number of subjects: 147
Study 21211103 — intervention group
Group type: EXPERIMENTAL
Intervention: Facemasks and intensified hand hygiene
Number of subjects: 147
Study 18721739 — intervention group
Group type: EXPERIMENTAL
Intervention: Chicken-based diet (CD)
Number of subjects: 28
Study 18721739 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (10 mg/day)
Number of subjects: 28
Study 17002935 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation; specific dosage and duration not available
Number of subjects: 0
Study 14586909 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance strengthening exercises (9 lower-extremity exercises, 3 times a week)
Number of subjects: 0
Study 14586909 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy with resistance
Number of subjects: 0
Study 11039742 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2%
Number of subjects: 188
Study 11039742 — intervention group
Group type: COMPARATOR
Intervention: Betaxolol 0.25%
Number of subjects: 188
Study 9526784 — intervention group
Group type: EXPERIMENTAL
Intervention: Names training group (n = 13)
Number of subjects: 34
Study 9526784 — intervention group
Group type: COMPARATOR
Intervention: Placebo training group (n = 10)
Number of subjects: 34
Study 9526784 — intervention group
Group type: COMPARATOR
Intervention: Retest control group (n = 11)
Number of subjects: 34
Study 8267700 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance resistance training once a week
Number of subjects: 18
Study 8267700 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance resistance training twice a week
Number of subjects: 18
Study 8267700 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups performing endurance training four times a week
Number of subjects: 18
Study 8267700 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 18
Study 4035232 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) alone or associated with conventional antihypertensive therapy
Number of subjects: 0
Study 31168928 — intervention group
Group type: EXPERIMENTAL
Intervention: E-scale weight measurements
Number of subjects: 248
Study 31168928 — intervention group
Group type: EXPERIMENTAL
Intervention: E-scale and clinic weight measurements taken on the same day
Number of subjects: 248
Study 30021886 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CTLA-4 therapy
Number of subjects: 181
Study 30021886 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 therapy
Number of subjects: 181
Study 30021886 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (anti-CTLA-4 and anti-PD-1)
Number of subjects: 181
Study 30641625 — intervention group
Group type: EXPERIMENTAL
Intervention: Xinfeng Capsule (XFC), 3 pills each time, 3 times per day for 3 months
Number of subjects: 58
Study 30641625 — intervention group
Group type: COMPARATOR
Intervention: Hydroxychloroquine (HCQ) Sulfate, 0.1 g per tablet, 2 tablets each time, twice per day for 3 months
Number of subjects: 58
Study 30641625 — intervention group
Group type: EXPERIMENTAL
Intervention: Xinfeng Capsule (XFC)
Number of subjects: 58
Study 30641625 — intervention group
Group type: COMPARATOR
Intervention: Hydroxychloroquine (HCQ) Sulfate
Number of subjects: 58
Study 24070401 — intervention group
Group type: EXPERIMENTAL
Intervention: Living cellular sheet (LCS; allogenic cultured keratinocytes and fibroblasts in bovine collagen)
Number of subjects: 0
Study 24070401 — intervention group
Group type: COMPARATOR
Intervention: Free gingival graft (FGG)
Number of subjects: 0
Study 22740509 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (2 g/day for 4 months)
Number of subjects: 62
Study 22740509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 20173020 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment (1 mg/m²·d) for 12 and 24 months
Number of subjects: 85
Study 20173020 — intervention group
Group type: COMPARATOR
Intervention: Control group (no GH treatment)
Number of subjects: 85
Study 20173020 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment
Number of subjects: 85
Study 17908978 — intervention group
Group type: EXPERIMENTAL
Intervention: LT plus ADV‐TK therapy
Number of subjects: 45
Study 17908978 — intervention group
Group type: COMPARATOR
Intervention: LT only
Number of subjects: 45
Study 17908978 — intervention group
Group type: EXPERIMENTAL
Intervention: LT plus ADV‐TK therapy (nonvascular invasion subgroup)
Number of subjects: 45
Study 17908978 — intervention group
Group type: COMPARATOR
Intervention: LT only (nonvascular invasion subgroup)
Number of subjects: 45
Study 15796730 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous antivenom (AV)
Number of subjects: 31
Study 15796730 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular antivenom (AV)
Number of subjects: 31
Study 12443837 — intervention group
Group type: EXPERIMENTAL
Intervention: Ospemifene 25 mg
Number of subjects: 40
Study 12443837 — intervention group
Group type: EXPERIMENTAL
Intervention: Ospemifene 50 mg
Number of subjects: 40
Study 12443837 — intervention group
Group type: EXPERIMENTAL
Intervention: Ospemifene 100 mg
Number of subjects: 40
Study 12443837 — intervention group
Group type: EXPERIMENTAL
Intervention: Ospemifene 200 mg
Number of subjects: 40
Study 12443837 — intervention group
Group type: EXPERIMENTAL
Intervention: Ospemifene (all doses)
Number of subjects: 40
Study 12443837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9860407 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha-2b (3 MU thrice weekly) and ribavirin (1000-1200 mg/daily per os) for 24 weeks
Number of subjects: 303
Study 9860407 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha-2b alone (6 MU thrice weekly) for 24 weeks
Number of subjects: 303
Study 8715357 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiologic serum
Number of subjects: 40
Study 8715357 — intervention group
Group type: COMPARATOR
Intervention: Non‐diluted hexetidine (Oraldine)
Number of subjects: 40
Study 2571203 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-Tac with CsA and prednisone
Number of subjects: 26
Study 2571203 — intervention group
Group type: COMPARATOR
Intervention: cyclosporine CsA and prednisone
Number of subjects: 26
Study 2571203 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-Tac with azathioprine and prednisone
Number of subjects: 26
Study 31270676 — intervention group
Group type: EXPERIMENTAL
Intervention: AR/AI-guidance for trocar insertion
Number of subjects: 20
Study 31270676 — intervention group
Group type: COMPARATOR
Intervention: Standard fluoroscopy for trocar insertion
Number of subjects: 20
Study 30361533 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning algorithms (extremely randomized tree with adaptive boosting)
Number of subjects: 330
Study 30361533 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental parameters optimization
Number of subjects: 330
Study 27422421 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional corticosteroid injection (40 mg methylprednisolone) at monthly intervals for 6 consecutive months
Number of subjects: 230
Study 26340806 — intervention group
Group type: EXPERIMENTAL
Intervention: Personally relevant items
Number of subjects: 8
Study 26340806 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic items
Number of subjects: 8
Study 26340806 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalization scripts (personally relevant)
Number of subjects: 8
Study 26340806 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalization scripts (generic)
Number of subjects: 8
Study 23060056 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard medical care plus chiropractic manipulative therapy (CMT)
Number of subjects: 100
Study 23060056 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care (SMC)
Number of subjects: 100
Study 21903774 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A4 T variant allele
Number of subjects: 185
Study 21903774 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A4 T allele plus CYP3A5*3/*3
Number of subjects: 185
Study 21903774 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A4 CC homozygotes plus CYP3A5*3/*3
Number of subjects: 185
Study 21903774 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A4 T allele with CYP3A5*3/*3
Number of subjects: 185
Study 21903774 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A4 CC homozygotes with CYP3A5*3/*3
Number of subjects: 185
Study 21903774 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A4 T allele carriers with CYP3A5*1
Number of subjects: 185
Study 21903774 — intervention group
Group type: COMPARATOR
Intervention: CYP3A4 CC homozygotes with CYP3A5*1
Number of subjects: 185
Study 18582308 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/ml hyperbaric lidocaine
Number of subjects: 100
Study 18582308 — intervention group
Group type: COMPARATOR
Intervention: 20 mg/ml hyperbaric lidocaine
Number of subjects: 100
Study 16956334 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic hysterectomy
Number of subjects: 125
Study 16956334 — intervention group
Group type: COMPARATOR
Intervention: Abdominal hysterectomy
Number of subjects: 125
Study 12862201 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 4 mg daily (candesartan group)
Number of subjects: 52
Study 12862201 — intervention group
Group type: COMPARATOR
Intervention: Control group (no candesartan)
Number of subjects: 52
Study 10828634 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% strontium nitrate
Number of subjects: 8
Study 10828634 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 8
Study 9346162 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate supplement (N = 17)
Number of subjects: 30
Study 9346162 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N = 13)
Number of subjects: 30
Study 8475236 — intervention group
Group type: COMPARATOR
Intervention: Consult (1-month rotation on the Psychiatry Consultation Service)
Number of subjects: 0
Study 8475236 — intervention group
Group type: COMPARATOR
Intervention: Liaison (31-hour workshops over 1 year)
Number of subjects: 0
Study 8475236 — intervention group
Group type: COMPARATOR
Intervention: Consult-plus-Liaison (both training programs experienced in consecutive years)
Number of subjects: 0
Study 8475236 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 2420164 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethmozine (10 mg/kg/day)
Number of subjects: 13
Study 2420164 — intervention group
Group type: COMPARATOR
Intervention: Ethmozine (maintenance therapy)
Number of subjects: 13
Study 31882387 — intervention group
Group type: EXPERIMENTAL
Intervention: Epsilon aminocaproic acid (EACA)
Number of subjects: 91
Study 31882387 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 91
Study 30165051 — intervention group
Group type: EXPERIMENTAL
Intervention: Sigmoidoscopy screening (n = 20,552)
Number of subjects: 98684
Study 30165051 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 78,126)
Number of subjects: 98684
Study 24389520 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric fatiguing contraction (20% of maximal strength) with cognitive stress (difficult mental math task)
Number of subjects: 39
Study 24389520 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric fatiguing contraction (20% of maximal strength) with cognitive stress (simple mental math task)
Number of subjects: 39
Study 24389520 — intervention group
Group type: COMPARATOR
Intervention: Isometric fatiguing contraction (20% of maximal strength) with no mental task (control)
Number of subjects: 39
Study 22715143 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-foot exercise (SFE)
Number of subjects: 24
Study 22715143 — intervention group
Group type: COMPARATOR
Intervention: Towel-curl exercise (TCE)
Number of subjects: 24
Study 22715143 — intervention group
Group type: COMPARATOR
Intervention: Both SFE and TCE
Number of subjects: 24
Study 19243745 — intervention group
Group type: EXPERIMENTAL
Intervention: P along with 6 mg E(2) valerate vaginally (group C)
Number of subjects: 270
Study 19243745 — intervention group
Group type: EXPERIMENTAL
Intervention: P along with 6 mg E(2) valerate orally (group B)
Number of subjects: 270
Study 19243745 — intervention group
Group type: COMPARATOR
Intervention: Only P (group A)
Number of subjects: 270
Study 18700216 — intervention group
Group type: EXPERIMENTAL
Intervention: Perphenazine
Number of subjects: 1445
Study 18700216 — intervention group
Group type: COMPARATOR
Intervention: Antipsychotic medications (general)
Number of subjects: 1445
Study 18700216 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication adherence
Number of subjects: 1445
Study 17171192 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin administration
Number of subjects: 0
Study 14500057 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 0
Study 14500057 — intervention group
Group type: COMPARATOR
Intervention: Endometrial ablation (EA)
Number of subjects: 0
Study 14500057 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterectomy and Endometrial ablation (EA)
Number of subjects: 0
Study 9589972 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (A)
Number of subjects: 0
Study 9589972 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment of RA using acupuncture (A)
Number of subjects: 0
Study 7905890 — intervention group
Group type: EXPERIMENTAL
Intervention: Urias A‐4 closed drainage system
Number of subjects: 181
Study 7905890 — intervention group
Group type: COMPARATOR
Intervention: Curity Infection Control System
Number of subjects: 181
Study 3947490 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% bupivacaine 2.7 ml at L2/3 (Group C)
Number of subjects: 40
Study 3947490 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% bupivacaine 2 ml at L3/4 (Group D)
Number of subjects: 40
Study 3947490 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine 4 ml at L3/4 (Group B)
Number of subjects: 40
Study 3947490 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% bupivacaine 2.7 ml at L3/4 (Group A)
Number of subjects: 40
Study 31416450 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive sexuality education for 1 month, conducted by qualified midwives, with at least two sessions per week focusing on various aspects of sexual health and abstinence.
Number of subjects: 363
Study 31416450 — intervention group
Group type: COMPARATOR
Intervention: Normal classes without additional intervention (control group).
Number of subjects: 363
Study 31416450 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive sexuality education for 1 month.
Number of subjects: 363
Study 31416450 — intervention group
Group type: COMPARATOR
Intervention: Normal classes (control group).
Number of subjects: 363
Study 31416450 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention based on the Health Belief Model (HBM).
Number of subjects: 363
Study 28201994 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate (2.5 mg once daily or 17.5 mg once weekly)
Number of subjects: 852
Study 26066773 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamine (300 mg in 0.9% Normal saline solution)
Number of subjects: 30
Study 26066773 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% Normal saline)
Number of subjects: 30
Study 26066773 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamine group
Number of subjects: 30
Study 26066773 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamine supplementation
Number of subjects: 30
Study 23177384 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 700
Study 23177384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 700
Study 21733421 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous local anesthetic mixture under the tourniquet
Number of subjects: 56
Study 21733421 — intervention group
Group type: COMPARATOR
Intervention: No additional anesthetic
Number of subjects: 56
Study 19812692 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 polyunsaturated fatty acid (PUFA) supplementation
Number of subjects: 0
Study 16501712 — intervention group
Group type: EXPERIMENTAL
Intervention: Flocculant-disinfectant
Number of subjects: 514
Study 16501712 — intervention group
Group type: COMPARATOR
Intervention: Standard water-handling practices
Number of subjects: 514
Study 15163169 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (100 mg/m2)
Number of subjects: 143
Study 11710658 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifting 90% of 1 repetition maximum (1RM) 5 times
Number of subjects: 0
Study 11710658 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifting 30% of 1 repetition maximum (1RM) 15 times
Number of subjects: 0
Study 9054277 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for carotid disease with duplex Doppler ultrasonography
Number of subjects: 1000
Study 9054277 — intervention group
Group type: COMPARATOR
Intervention: No screening
Number of subjects: 1000
Study 7506146 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide treatment for 7 to 10 days
Number of subjects: 0
Study 7506146 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide in combination with ambroxol
Number of subjects: 0
Study 7506146 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide with concomitant antibacterial
Number of subjects: 0
Study 3725477 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest shielded with aluminum foil while on phototherapy (36 babies)
Number of subjects: 74
Study 3725477 — intervention group
Group type: COMPARATOR
Intervention: No shield (38 babies)
Number of subjects: 74
Study 30105266 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarkers collected on the day of ACL reconstruction (specifically sf IL-1α, IL-1ra, MMP-9)
Number of subjects: 22
Study 30105266 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarkers collected on the day of ACL reconstruction (specifically sf IL-1α)
Number of subjects: 22
Study 26653067 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention with monthly motivational counselling calls and weekly personalised text messages for 12 months
Number of subjects: 637
Study 26653067 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention (participants receiving more than 75% of calls)
Number of subjects: 637
Study 26653067 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention
Number of subjects: 637
Study 26653067 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 637
Study 24566244 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (0.5 to 3.5 vol%) and Remifentanil (0 to 12 ng/ml)
Number of subjects: 40
Study 24566244 — intervention group
Group type: COMPARATOR
Intervention: Pre-stimulation measures
Number of subjects: 40
Study 24566244 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-stimulation measures
Number of subjects: 40
Study 23135014 — intervention group
Group type: EXPERIMENTAL
Intervention: Icon(R)Life LLIN
Number of subjects: 0
Study 23135014 — intervention group
Group type: COMPARATOR
Intervention: Control (no net and untreated net)
Number of subjects: 0
Study 20121764 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-fine beclomethasone/formoterol (BDP/F) 400/24 microg daily
Number of subjects: 30
Study 20121764 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate/salmeterol (FP/S) 500/100 microg daily
Number of subjects: 30
Study 18382802 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary shunts
Number of subjects: 100
Study 18382802 — intervention group
Group type: COMPARATOR
Intervention: Shuntless operations (Control)
Number of subjects: 100
Study 15985318 — intervention group
Group type: EXPERIMENTAL
Intervention: ND 5.5 device
Number of subjects: 0
Study 15985318 — intervention group
Group type: COMPARATOR
Intervention: XR-1 device
Number of subjects: 0
Study 15985318 — intervention group
Group type: EXPERIMENTAL
Intervention: ND 5.5 device with 2 administrations
Number of subjects: 0
Study 15985318 — intervention group
Group type: EXPERIMENTAL
Intervention: ND 5.5 and XR-1 devices
Number of subjects: 0
Study 11950378 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg once daily
Number of subjects: 0
Study 10520055 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (200 microg, twice daily)
Number of subjects: 46
Study 10520055 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 46
Study 7741338 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant/child CPR training (4-hour program)
Number of subjects: 83
Study 7741338 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CPR training)
Number of subjects: 83
Study 1675050 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen sodium 0.03% (topically administered to one eye)
Number of subjects: 20
Study 1675050 — intervention group
Group type: COMPARATOR
Intervention: Placebo (topically administered to the contralateral eye)
Number of subjects: 20
Study 7023522 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (12 patients)
Number of subjects: 20
Study 7023522 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCT) (8 patients)
Number of subjects: 20
Study 7023522 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril + HCT
Number of subjects: 20
Study 7023522 — intervention group
Group type: COMPARATOR
Intervention: HCT + Captopril
Number of subjects: 20
Study 30876469 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified GLB™ program + personalized, genetic-based lifestyle advice for weight management
Number of subjects: 0